StockData
aTYR PHARMA INC logo

aTYR PHARMA INC (ATYR) stock

ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$4.99−0.25 (-4.77%)

Close on Nov 17, 2026Market cap $489.46MP/E –Yield –

aTYR PHARMA r&d expenses

Research and development expenses are spending on new products and technology.

aTYR PHARMA's R&D Expenses for the twelve months ending Jun 30, 2026 was $47.09M, down 13.2% year over year. For fiscal 2025 it was $60.22M, up 10.8% from the year before. Over ten years it grew 5.7% a year on average. The highest annual figure on record is $60.22M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$60.22M+10.8%
FY2024Dec 31, 2024$54.37M+28.6%
FY2023Dec 31, 2023$42.29M-1.2%
FY2022Dec 31, 2022$42.81M+84.0%
FY2021Dec 31, 2021$23.26M+34.5%
FY2020Dec 31, 2020$17.29M+23.1%
FY2019Dec 31, 2019$14.05M-31.1%
FY2018Dec 31, 2018$20.39M-32.2%
FY2017Dec 31, 2017$30.07M-29.8%
FY2016Dec 31, 2016$42.85M+24.2%
FY2015Dec 31, 2015$34.50M+105.7%
FY2014Dec 31, 2014$16.78M+21.3%
FY2013Dec 31, 2013$13.83M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$6.75M-56.1%
Q1 FY2026Mar 31, 2026$7.32M-38.1%
Q4 FY2025Dec 31, 2025$10.89M-10.9%
Q3 FY2025Sep 30, 2025$22.13M+49.5%
Q2 FY2025Jun 30, 2025$15.38M+10.1%
Q1 FY2025Mar 31, 2025$11.81M-11.6%
Q4 FY2024Dec 31, 2024$12.23M-4.1%
Q3 FY2024Sep 30, 2024$14.81M+43.5%
Q2 FY2024Jun 30, 2024$13.97M+42.0%
Q1 FY2024Mar 31, 2024$13.36M+42.5%
Q4 FY2023Dec 31, 2023$12.76M-14.5%
Q3 FY2023Sep 30, 2023$10.32M+4.6%
Q2 FY2023Jun 30, 2023$9.84M+7.7%
Q1 FY2023Mar 31, 2023$9.38M+5.4%
Q4 FY2022Dec 31, 2022$14.91M+150.4%
Q3 FY2022Sep 30, 2022$9.87M+92.0%
Q2 FY2022Jun 30, 2022$9.14M+19.3%
Q1 FY2022Mar 31, 2022$8.90M+97.0%
Q4 FY2021Dec 31, 2021$5.96M+26.8%
Q3 FY2021Sep 30, 2021$5.14M+11.3%
Q2 FY2021Jun 30, 2021$7.66M+75.5%
Q1 FY2021Mar 31, 2021$4.52M+24.9%
Q4 FY2020Dec 31, 2020$4.70M+30.9%
Q3 FY2020Sep 30, 2020$4.62M+21.5%
Q2 FY2020Jun 30, 2020$4.36M+31.6%
Q1 FY2020Mar 31, 2020$3.62M+8.1%
Q4 FY2019Dec 31, 2019$3.59M+1.2%
Q3 FY2019Sep 30, 2019$3.80M-9.6%
Q2 FY2019Jun 30, 2019$3.31M-48.9%
Q1 FY2019Mar 31, 2019$3.35M-45.6%
Q4 FY2018Dec 31, 2018$3.55M-33.2%
Q3 FY2018Sep 30, 2018$4.20M-41.1%
Q2 FY2018Jun 30, 2018$6.48M-23.0%
Q1 FY2018Mar 31, 2018$6.15M-33.2%
Q4 FY2017Dec 31, 2017$5.31M-41.9%
Q3 FY2017Sep 30, 2017$7.13M-31.4%
Q2 FY2017Jun 30, 2017$8.42M–
Q1 FY2017Mar 31, 2017$9.20M–
Q4 FY2016Dec 31, 2016$9.14M–
Q3 FY2016Sep 30, 2016$10.40M–

More aTYR PHARMA figures

See a number that looks wrong?